TMFUltraLong

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the health care sector, but also has a penchant for mining, retail, and automotive stocks, as well as personal finance and macroeconomic topics of interest.

TMFUltraLong’s Activity

Yesterday

NL

Article

TMFUltraLong published an article 3:19 PM

Why Catalyst Pharmaceutical Partners, Inc. Shares Are Being Decimated

Catalyst Pharmaceutical Partners' shareholders discover that two's a crowd.

NL

Article

TMFUltraLong published an article 1:39 PM

Why ResMed Inc. Shares Are Getting Clobbered

ResMed shareholders certainly aren't breathing easy after the company released its third-quarter earnings results. Find out if this dip is a buying opportunity or a warning to stay away.

Thu Apr 23

NL

Article

TMFUltraLong published an article 12:00 AM

Amgen, Inc. Earnings: 4 Things You Probably Overlooked

Amgen delivered another solid earnings beat in the first quarter, but if you just skimmed the headlines you probably missed these four important points.

Tue Apr 21

NL

Article

TMFUltraLong published an article 5:24 PM

Why Advaxis, Inc. Shares Lifted Off

Advaxis shares rocket higher after presenting new data at the American Association for Cancer Research's annual meeting. Find out if Advaxis shares can head even higher.

NL

Article

TMFUltraLong published an article 3:42 PM

Why Mylan NV Is Suddenly in the Driver's Seat

Find out why Mylan's merger and acquisitions "triangle" has the generic drugmaker sitting pretty.

Mon Apr 20

NL

Article

TMFUltraLong published an article 12:00 AM

10 Most Hated Companies in Healthcare

When emotional trading is on display, the short-sellers come out to play. Find out which companies are the most hated in healthcare, why they're so universally disliked, and which company may eventually deserve a reprieve.

NL

Article

TMFUltraLong published an article 12:00 AM

Thanks, But No Thanks! 3 Wall Street "Strong Buys" We Wouldn't Touch

Analyst ratings are often given some degree of precedence by investors, but not all of their ratings appear to make sense. We asked three of our top analysts for a Wall Street "strong buy" rating that didn't make sense to them, and this is what they [more]

Wed Apr 15

NL

Article

TMFUltraLong published an article 12:00 AM

Pain-Free Blood Tests? Sign Me Up!

A small, Wisconsin-based company could be on the verge of developing a revolutionary new blood test that is virtually pain-free. Find out how personalized healthcare is transforming the medical field.

NL

Article

TMFUltraLong published an article 12:00 AM

Johnson & Johnson Earnings: 5 Initial Takeaways

Johnson & Johnson's headline figures don't tell the full story behind its first-quarter earnings report. Dig a bit deeper to uncover these five key takeaways.

NL

Article

TMFUltraLong published an article 12:00 AM

Is InvenSense Inc. Worthy of This Upgrade and 33% Price Target Hike?

Well off its 52-week high, MEMS-maker InvenSense catches a substantial upgrade and price target hike from one Wall Street firm. Find out whether this positive shift is deserved or wishful thinking.

Tue Apr 14

NL

Article

TMFUltraLong published an article 12:00 AM

How to Invest Money in Biotech

If you want to invest money in biotech, you first need to understand what catalysts tend to determine biotech stock valuations, and what your three best pathways are to becoming a successful biotech investor.

NL

Article

TMFUltraLong published an article 12:00 AM

5 Frightening Retirement Statistics That Demonstrate Baby Boomers Are in Serious Trouble

The stock market may be well off its 2009 lows, but a sizable number of baby boomers are still in very poor financial shape leading up to, and into their retirement. Here are five recent statistics that show just how serious a problem boomers could [more]

NL

Article

TMFUltraLong published an article 12:00 AM

15 Wise Moves to Make With Your Enormous Tax Refund

According to the latest figures from the IRS, the average tax refund in 2014 totaled nearly $2,900. Here are 15 novel ways you can wisely put that money to work if you were on the receiving end of money from the U.S. government.

Mon Apr 13

NL

Article

TMFUltraLong published an article 12:00 AM

Best Pure Play Investment in Cancer Drugs

Global cancer drug sales could soon soar past $100 billion, making this pure play in cancer drugs a stock you should seriously consider owning.

NL

Article

TMFUltraLong published an article 12:00 AM

President Obama Crushes the Marijuana Movement With 15 Words

While speaking in Jamaica, President Obama had some very stark words about the future of the marijuana industry within the United States.

NL

Article

TMFUltraLong published an article 12:00 AM

3 Megatrends in Healthcare

These three megatrends could be largely responsible for value creation and the impetus for innovation within the healthcare sector throughout the remainder of the decade.

NL

Article

TMFUltraLong published an article 12:00 AM

3 Worrisome Obamacare Trends That Could Put Its Long-Term Success in Jeopardy

Certain aspects of Obamacare have been an early success, but these three trends suggest that it could still just as easily fail to deliver on its promise of improving the healthcare landscape for consumers.

NL

Article

TMFUltraLong published an article 12:00 AM

Would You Have Guessed This Is the Apparel Retailer Consumers Are Most Loyal to?

U.S. apparel sales have more than doubled since 1992, but so have the number of retail choices for consumers. Find out which surprising apparel retailer is the best at creating loyal customers, according to this latest study.

NL

Article

TMFUltraLong published an article 12:00 AM

Meet the Game-Changing Drug Designed to Fight America's Leading Cause of Death

This disease claimed more than 600,000 lives in the U.S. in 2013, according to the CDC, but an experimental drug with a possible approval date in 2015 could put a dent in these mortality figures going forward.

NL

Article

TMFUltraLong published an article 12:00 AM

3 Value Stocks Near 52-Week Lows Worth Buying

These three value stocks may have been clobbered in recent months, but they all may be poised for substantial rebounds.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 99.87
Player Rank 97 out of 75215
Score 8548.52
Score Change Today -12.44
Accuracy 87.73%
Active Picks 105
Total Picks 506
Best Pick FAZ (+316.82)
Worst Pick PCYC (-8718.18)
Average Score per Pick 17.03
Charms Earned 16
Highest Rated Favorite TMFBabo
Go to TMFUltraLong’s CAPS page

Boards Stats & Trivia

CAPS All Star
Board Posts 3
Recs Received 11
People who have rec'd these posts 11
Recs to Posts Ratio (last 30 days) N/A
Threads Started 2
Threads Started Percentage 66.67 %
Most Frequent Board CAPS Feedback
Very First Post Tickering....Just a heads up... (10/14/2010)
Percentage of Posts Rec'd 100.00 %
Show TMFUltraLong’s 10 Latest Posts